Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-389949 in Healthy Subjects

NCT02099201 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Subjects

Interventions

DRUG: ACT-389949 40 mg
DRUG: ACT-389949 200 mg
DRUG: ACT-389949 800 mg
DRUG: ACT-389949 (Group C1 dose to be selected)
DRUG: ACT-389949 (Group C2 dose to be selected)
DRUG: Placebo

Sponsor

Idorsia Pharmaceuticals Ltd.